Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Cue Biopharma's Days Payable or its related term are showing as below:
FRA:1UC0's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.715 * Ranked among companies with meaningful Days Payable only.
Cue Biopharma's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
The historical data trend for Cue Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1UC0 vs CNTB, CDXS, HURA: Days Payable Comparison
For the Biotechnology subindustry, Cue Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cue Biopharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (FRA:1UC0) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #999999 out of 704 companies in the Biotechnology industry.
Is Cue Biopharma's Days Payable too high?
Cue Biopharma's current Days Payable is 0.00. Based on the distribution chart, Cue Biopharma ranks #999999 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cue Biopharma has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Days Payable compare to CNTB and CDXS?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #999999 out of 704 companies for Days Payable. This places Cue Biopharma in the lower half of its industry. The industry median Days Payable is 112.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cue Biopharma and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (FRA:1UC0) is currently considered Possible Value Trap. The stock's GF Value™ is €52.22, compared to a current price of €22.44 — trading 57% below its estimated fair value. The current Days Payable is 0.00. Cue Biopharma's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cue Biopharma (FRA:1UC0), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cue Biopharma (FRA:1UC0) Overvalued in 2026?
Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued.
The current stock price of €22.44 is trading 57% below its estimated GF Value™ of €52.22.
GuruFocus considers Cue Biopharma to be Possible Value Trap.
Key valuation signals for FRA:1UC0:
Days Payable: 0.00
GF Value™: €52.22 vs. price of €22.44 (57% below fair value)
No single metric tells the full story. See the FRA:1UC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
46GF Score
Get the complete analysis for FRA:1UC0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1UC0 has been successfully added to your 
